LEARNING OBJECTIVES

Complete resection to no gross residual disease (R0) is the most important prognostic indicator of survival in epithelial ovarian cancer. 
HIPEC is indicated in patients with Stage III ovarian cancer at interval cytoreductive surgery (ICS) following neoadjuvant chemotherapy, and can be considered for select stage IV patients who have a favorable response to neoadjuvant therapy. 
HIPEC is considered controversial in the management of ovarian cancer due to a history of mixed study results, increased toxicities, and institutional variably to access. HIPEC has only recently entered into official society consensus guidelines.